RS64288B9 - Kompozicije agonisti gip/glp1 - Google Patents

Kompozicije agonisti gip/glp1

Info

Publication number
RS64288B9
RS64288B9 RS20230480A RSP20230480A RS64288B9 RS 64288 B9 RS64288 B9 RS 64288B9 RS 20230480 A RS20230480 A RS 20230480A RS P20230480 A RSP20230480 A RS P20230480A RS 64288 B9 RS64288 B9 RS 64288B9
Authority
RS
Serbia
Prior art keywords
gip
agonist compositions
glp1 agonist
glp1
compositions
Prior art date
Application number
RS20230480A
Other languages
English (en)
Inventor
Vincent John Corvari
Christopher Sears Minie
Dinesh Shyandeo Mishra
Ken Kangyi Qian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67263049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64288(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS64288B1 publication Critical patent/RS64288B1/sr
Publication of RS64288B9 publication Critical patent/RS64288B9/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
RS20230480A 2018-06-22 2019-06-14 Kompozicije agonisti gip/glp1 RS64288B9 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688632P 2018-06-22 2018-06-22
EP19739766.4A EP3810201B9 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions
PCT/US2019/037146 WO2019245893A2 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions

Publications (2)

Publication Number Publication Date
RS64288B1 RS64288B1 (sr) 2023-07-31
RS64288B9 true RS64288B9 (sr) 2023-11-30

Family

ID=67263049

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230480A RS64288B9 (sr) 2018-06-22 2019-06-14 Kompozicije agonisti gip/glp1

Country Status (33)

Country Link
US (2) US11357820B2 (sr)
EP (2) EP3810201B9 (sr)
JP (3) JP6896945B2 (sr)
KR (3) KR102523489B1 (sr)
CN (1) CN112312926A (sr)
AR (1) AR115542A1 (sr)
AU (2) AU2019289110B2 (sr)
BR (1) BR112020023452A2 (sr)
CA (1) CA3103469C (sr)
CL (1) CL2020003359A1 (sr)
CR (1) CR20200634A (sr)
DK (1) DK3810201T5 (sr)
EA (1) EA202092713A1 (sr)
EC (1) ECSP20082717A (sr)
ES (1) ES2953740T3 (sr)
FI (1) FI3810201T3 (sr)
HR (1) HRP20230748T1 (sr)
HU (1) HUE063059T2 (sr)
IL (2) IL295433B2 (sr)
JO (1) JOP20200335A1 (sr)
LT (1) LT3810201T (sr)
MA (1) MA52965B1 (sr)
MD (1) MD3810201T2 (sr)
MX (1) MX2020013727A (sr)
PE (1) PE20210049A1 (sr)
PH (1) PH12020552215A1 (sr)
PL (1) PL3810201T3 (sr)
PT (1) PT3810201T (sr)
RS (1) RS64288B9 (sr)
SG (1) SG11202012744UA (sr)
SI (1) SI3810201T1 (sr)
TW (1) TWI705820B (sr)
WO (1) WO2019245893A2 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019038412A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A/S GLP-1 COMPOSITIONS AND USES THEREOF
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
MA53390A (fr) * 2018-07-23 2021-06-02 Lilly Co Eli Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie
WO2020106754A1 (en) * 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
AU2021207313A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Pharmaceutical formulations
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022247950A1 (zh) * 2021-05-28 2022-12-01 广东众生睿创生物科技有限公司 多肽的制备及其应用
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
WO2024006662A1 (en) * 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
WO1999051272A1 (en) * 1998-04-03 1999-10-14 Chiron Corporation Injectable igf-formulations containing succinate as buffering agent
HU229208B1 (en) 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
PT3300721T (pt) 2003-11-20 2019-06-06 Novo Nordisk As Formulações peptidicas contendo propileno glicol que sao ideais para a produção e para utilizacao em dispositivos de injeção
CA2589647A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations
BRPI0613731A2 (pt) * 2005-07-12 2011-02-01 Renovo Ltd composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta
CN104288756A (zh) * 2006-04-14 2015-01-21 曼金德公司 高血糖素样肽1(glp-1)药物制剂
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
WO2009009562A2 (en) 2007-07-10 2009-01-15 Eli Lilly And Company Glp-1-fc fusion protein formulation
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
PL2708252T3 (pl) 2010-03-01 2016-01-29 Lilly Co Eli Automatyczne urządzenie do iniekcji z mechanizmem opóźniającym zawierające dwufunkcyjny element przemieszczający
RS56173B1 (sr) * 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
CA2877056A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
SG11201810102SA (en) * 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Also Published As

Publication number Publication date
US11357820B2 (en) 2022-06-14
DK3810201T5 (da) 2023-08-21
JP7413315B2 (ja) 2024-01-15
RS64288B1 (sr) 2023-07-31
EP3810201A2 (en) 2021-04-28
IL295433A (en) 2022-10-01
SI3810201T1 (sl) 2023-08-31
CL2020003359A1 (es) 2021-06-25
AU2019289110A1 (en) 2021-01-21
JP2024041808A (ja) 2024-03-27
HUE063059T2 (hu) 2023-12-28
MA52965B1 (fr) 2023-08-31
CA3103469C (en) 2024-04-09
MX2020013727A (es) 2021-03-02
DK3810201T3 (da) 2023-06-26
TWI705820B (zh) 2020-10-01
CN112312926A (zh) 2021-02-02
JP2021167314A (ja) 2021-10-21
AU2022279524A1 (en) 2023-02-02
AR115542A1 (es) 2021-01-27
PE20210049A1 (es) 2021-01-08
JP2021506952A (ja) 2021-02-22
FI3810201T3 (fi) 2023-08-17
IL295433B2 (en) 2024-03-01
KR20210010572A (ko) 2021-01-27
KR20230058172A (ko) 2023-05-02
ECSP20082717A (es) 2021-01-29
IL279504B (en) 2022-09-01
CA3103469A1 (en) 2019-12-26
SG11202012744UA (en) 2021-01-28
EA202092713A1 (ru) 2021-04-05
WO2019245893A2 (en) 2019-12-26
KR20240060873A (ko) 2024-05-08
HRP20230748T1 (hr) 2023-10-27
EP3810201B1 (en) 2023-06-07
WO2019245893A3 (en) 2020-03-12
KR102523489B1 (ko) 2023-04-21
JP6896945B2 (ja) 2021-06-30
EP4257185A3 (en) 2024-01-17
US11918623B2 (en) 2024-03-05
PH12020552215A1 (en) 2021-06-28
IL279504A (en) 2021-01-31
PL3810201T3 (pl) 2023-09-25
LT3810201T (lt) 2023-07-25
MD3810201T2 (ro) 2023-11-30
PT3810201T (pt) 2023-07-04
ES2953740T3 (es) 2023-11-15
EP4257185A2 (en) 2023-10-11
CR20200634A (es) 2021-01-21
EP3810201B9 (en) 2023-08-02
IL295433B1 (en) 2023-11-01
TW202015717A (zh) 2020-05-01
BR112020023452A2 (pt) 2021-02-23
US20220273762A1 (en) 2022-09-01
MA52965A (fr) 2021-04-28
US20190388502A1 (en) 2019-12-26
AU2019289110B2 (en) 2022-10-06
JOP20200335A1 (ar) 2020-12-20

Similar Documents

Publication Publication Date Title
IL279504A (en) GIP/GLP1 agonist compounds
IL279827A (en) GIP/GLP1 co-agonist compounds
GB201911800D0 (en) Antiflouling Composition
GB201820878D0 (en) Composition
GB201811100D0 (en) Composition
GB201810492D0 (en) Composition
GB2606975B (en) Composition
GB201804434D0 (en) Composition
GB2583851B (en) Composition
GB201909924D0 (en) Composition
GB201901161D0 (en) Composition
GB201818827D0 (en) Composition
GB201819861D0 (en) Composition
GB201815032D0 (en) Composition
GB201809123D0 (en) Composition
GB201801596D0 (en) Composition
GB201913398D0 (en) Composition
GB201820082D0 (en) Composition
GB201818567D0 (en) Composition
GB201815704D0 (en) Composition
GB201815420D0 (en) Composition
GB201813442D0 (en) Composition
GB201811889D0 (en) Composition
GB201811149D0 (en) Composition
GB201810024D0 (en) Composition